Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Zhang, Jia Xing ^a   Cai, Man Bo ^a   Wang, Xiao Pai ^a   Duan, Li Ping ^b   Shao, Qiong ^a   Tong, Zhu Ting ^c   Liao, Ding Zhun ^a   Li, Yang Yang ^a   Huang, Ma Yan ^a   Zeng, Yi Xin ^a   Shao, Jian Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INSTITUTE OF SCIENTIFIC AND TECHNICAL INFORMATION OF CHINA   (China)

^c The First Affiliated Hospital of Anhui25 Medical University   (China)

Author keywords

DLL4; Immunohistochemistry; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

DELTA LIKE LIGAND 4; NOTCH RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; DLL4 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER; VASCULOTROPIN A;

ADULT; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; COMPUTER PROGRAM; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ADOLESCENT; AGED; AREA UNDER THE CURVE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BLOTTING, WESTERN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84880592124     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0390-x     Document Type: Article

References (43)

1. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765-77.
2. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54.
3. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:421-9.
4. Farias TP, Dias FL, Lima RA, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:794-9.
5. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol. 1986;33:194-7.
6. Petrovich Z, Cox JD, Roswit B, et al. Advanced carcinoma of the nasopharynx. A clinical study of 274 patients. Radiology. 1982;144:905-8.
7. Geara FB, Sanguineti G, Tucker SL, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol. 1997;43:53-61.
8. Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet. 2002;31:395-9.
9. Bei JX, Li Y, Jia WH, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42:599-603.
10. Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009;119:3626-36.
11. Cheng AL, Huang WG, Chen ZC, et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res. 2008;14:435-45.
12. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-95.
13. Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. BioEssays. 2004;26:225-34.
14. Gridley T. Notch signaling during vascular development. Proc Natl Acad Sci USA. 2001;98:5377-8.
15. Shutter JR, Scully S, Fan W, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000;14:1313-8.
16. Rao PK, Dorsch M, Chickering T, et al. Isolation and characterization of the notch ligand delta4. Exp Cell Res. 2000;260:379-86.
17. Patel NS, Li JL, Generali D, et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005;65:8690-7.
18. Williams CK, Li JL, Murga M, et al. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107:931-9.
19. Liu ZJ, Shirakawa T, Li Y, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003;23:14-25.
20. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032-7.
21. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444:1083-7.
22. Li JL, Sainson RC, Shi W, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67:11244-53.
23. Li JL, Sainson RC, Oon CE, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71:6073-83.
24. Martinez JC, Muller MM, Turley H, et al. Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 2009;54:598-606.
25. Schadler KL, Zweidler-McKay PA, et al. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res. 2010;16:848-56.
26. Patel NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res. 2006;12:4836-44.
27. Engin F, Bertin T, Ma O, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009;18(8):1464-70.
28. Jubb AM, Soilleux EJ, Turley H, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol. 2010;176:2019-28.
29. Donnem T, Andersen S, Al-Shibli K, et al. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 2010;116:5676-85.
30. Jubb AM, Miller KD, Rugo HS, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011;17:372-81.
31. Jubb AM, Turley H, Moeller HC, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009;101:1749-57.
32. Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008;6:1.
33. Min H, Hong M, Ma J, et al. A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994;30:1037-42.
34. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252-9.
35. Raeside DE. Monte Carlo principles and applications. Phys Med Biol. 1976;21:181-97.
36. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23:1118-24.
37. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48-50.
38. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65-71.
39. Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009;5:168-77.
40. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci. 2009;14:3094-110.
41. Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 2007;13:7243-6.
42. Chen FH, Chiang CS, Wang CC, et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res. 2009;15:1721-9.
43. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8:2595-604.